On September 10, 2019, Aimed Alliance was joined by 9 other advocacy organizations to request that the Blue Cross Blue Shield of Michigan health plan end its nonmedical switching practices. This complaint arose as a result of the health plan’s decision to transition patients with conditions like rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn’s disease off of their current treatment and onto a biosimilar product by Nov. 1, 2019. This letter warned of the dangers of removing coverage of a medication that patients are currently stable on in the middle of the plan year. Additionally, this letter requested that patients be allowed to stay on their current medication through the end of the plan year. Explore this issue further by reviewing our letter.